Member Info for dafad

Full announcment here

https://www.share-talk.com/vault-ventures-plc-aqse-vult-announces-entry-into-post-quantum-security-infrastructure/

Post-quantum encryption as a structural requirement

Advances in quantum computing are widely expected, over time, to compromise many of the cryptographic standards currently relied upon to secure digital communications, data storage and transaction systems.

As a result, the transition to post-quantum encryption – cryptographic methods designed to remain secure against both classical and quantum-enabled attacks – is increasingly regarded as an inevitable evolution of digital security rather than a speculative future risk.

Vault believes that post-quantum encryption will become a core component of secure digital infrastructure as organisations prepare for future computing capabilities while continuing to safeguard long-lived data today.

Vault Ventures PLC (the “Company” or “Vault”) announces its entry into post-quantum security infrastructure, with an initial emphasis on post-quantum encryption at the application layer.

Highlights

· Vault announces entry into post-quantum security infrastructure, reflecting its focus on long-term, foundational digital systems

· Initial emphasis on post-quantum encryption at the application layer, rather than quantum hardware or theoretical research

· Strategic relevance to high-trust and regulated environments where long-term data security is critical, including legal and professional services, financial services and other regulated industries.

· Approach aligned with Vault’s platform strategy of selective investment, incubation and long-term ownership

This strategic development is aligned with Vault’s established positioning as a builder and owner of foundational digital infrastructure and systems designed to operate over long time horizons, particularly within high-trust and regulated environments. The Company’s focus remains on identifying structural shifts in technology early and developing assets that become critical as those shifts move from theory into practical deployment.

In parallel with development of the UK Facility, HyProMag is rolling out HPMS technology into Germany and the USA, and is also evaluating other jurisdictions including Japan, Canada and South Korea.

Expansion of equipment and knowledge keeps pushing the boundaries of what we are achieving and this commercial scale facility at Tyseley is no exception, with results achieved in our commercial runs already exceeding results at the pilot facility. HyProMag are well placed to maximise this opportunity and further develop magnet supply opportunities both in the UK and overseas. Our expanding team is excited by this next phase of our development."

MINISTER FOR INDUSTRY OFFICIALLY OPENS RARE EARTH MAGNET RECYCLING AND MANUFACTURING FACILITY AT TYSELEY ENERGY PARK, BIRMINGHAM

London / Vancouver: January 15, 2026 - Mkango Resources Ltd. (AIM/TSX-V: MKA) ("Mkango") is pleased to announce the official launch of the rare earth magnet facility today at Tyseley Energy Park (the "Facility"). The Facility has been developed by the Magnetic Materials Group ("MMG") at the University of Birmingham and constructed and commissioned alongside HyProMag Limited ("HyProMag"). The University of Birmingham and HyProMag today host the opening of the Facility for separating and recycling rare earth magnets using the patented Hydrogen Processing of Magnet Scrap ("HPMS") technology, licensed exclusively to HyProMag. The Facility will be officially opened by Chris McDonald MP, Minister for Industry in the Department for Energy Security and Net Zero and the Department for Business and Trade.

The Facility at Tyseley Energy Park has enabled the first commercial rare earth magnet production in the UK in 25 years - making it a key enabler of UK Government's November 2025 Critical Minerals Strategy which sets targets for the UK to meet 10% of annual critical mineral demand by domestic sources, and 20% to be met through recycling by 2035.

The Facility is the only commercial scale rare earth sintered magnet manufacturing facility in the UK. HyProMag has successfully operated the Facility as the industrial partner, utilising the HPMS technology to produce a recycled NdFeB alloy powder, as well as having produced recycled NdFeB sintered magnet blocks utilising the recycled alloy powder. The Facility can recover over 400kg of rare earth alloy per batch utilising the HPMS reactor and can produce new sintered magnets from the recycled rare earth alloy at a capacity of 100 tonnes per annum on a single shift, and over 300 tonnes per annum on multiple shifts. Rare earth elements are amongst the key critical minerals featured in the UK's Critical Minerals Strategy, with their main commercial use being in rare earth permanent magnets. These magnets are required in electric vehicle traction motors and wind turbine generators, and they are also a key component in electronic devices including mobile phones, hard disk drives and loudspeakers, as well as being utilised in critical sectors such as aerospace and defence.

Myles has some thoughts here

https://x.com/MarcusP14709438

Completed concept studies for expansion of South Carolina and Nevada hubs, increasing total HyProMag USA magnet and alloy production from 1,552 metric tons NdFeB to 4,656 metric tons NdFeB per annum, supporting scalable U.S. manufacturing strategy and reinforcing momentum towards a planned U.S. public listing

· Greater than $2 billion post-tax NPV and 38.7% real IRR for expanded developments, based on forecast market prices[i], support commencement of pre-feasibility studies for the expansions

FOLLOWING COMPLETION OF EXPANSION CONCEPT STUDIES HYPROMAG USA ADVANCES EXPANSION TO THREE STATES SUPPORTING A PATH TO

TRIPLE U.S. RARE EARTH MAGNET CAPACITY BY 2029

Https://www.londonstockexchange.com/news-article/MKA/hypromag-usa-advances-expansion-to-three-states/17408086

Takeover target at this mkt cap

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "This patent allowance strengthens both the scientific and commercial foundations of our PTSD programme. It reflects our strategy of combining rigorous neuroscience with disciplined medicinal chemistry to build differentiated, scalable CNS therapeutics."

Solvonis Therapeutics plc

("Solvonis" or the "Company")

U.S. Patent allowance received for PTSD discovery programme

Demonstrating scientific and commercial significance

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States Patent and Trademark Office ("USPTO") for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder ("PTSD") discovery programme. One compound from this series is currently being evaluated alongside other candidates, with a lead compound expected to be selected in Q1 2026 in line with prior guidance.

The Allowance strengthens the intellectual property foundations of SVN-SDN-14 at an important stage as the programme advances toward lead-candidate selection. In addition to this IP milestone, the Company is highlighting the scientific significance of the newly protected compounds in addressing long-standing challenges in the development of next-generation PTSD therapeutics.

Https://www.londonstockexchange.com/news-article/SVNS/us-patent-allowance-for-ptsd-discovery-programme/17401871

Vast" or the "Company")

Proposed Acquisition of Gulf International Minerals Limited,

Reverse Takeover and Suspension from trading on AIM,

Proposed Placing to raise approximately £7.5 million

Deferral of Debt Facility Repayment Dates

Vast Resources plc, the AIM quoted mining company, is pleased to announce that it has entered into a conditional share purchase agreement ("SPA") with Bay Square Pacific Ltd ("Bay Square" or the "Seller") and a deed of contribution and guarantee with Bay Square and the shareholders of Bay Square (the "Seller Shareholders") (the "Acquisition Agreements"). Pursuant to the Acquisition Agreements, the Company has conditionally agreed to acquire 100% of the share capital of Gulf International Minerals Limited (the "Acquisition") for all share consideration, to be satisfied by the issue of new ordinary shares of 0.1p each in the Company ("Ordinary Shares") to the Seller and the Seller Shareholders representing 80% of the issued Ordinary Shares upon Completion of the Acquisition, including the Placing Shares and Bookbuild Offer Shares (both as defined below) (the "Enlarged Ordinary Share Capital on Re-Admission") (the "Proposed Transaction"). The conditions to the SPA and key terms of the Acquisition Agreements are summarised below.

In conjunction with the Proposed Transaction, the Company intends to conduct a placing of new Ordinary Shares, currently expected to raise approximately £7.5 million ("Placing") in the capital of the Company ("Placing Shares"). In addition, the Company intends to launch a retail offering to, inter alios, the Company's existing shareholders through the issue of new Ordinary Shares (the "Bookbuild Offer Shares").

The Proposed Transaction constitut

Rns out

Https://www.newswire.ca/news-releases/exim-bank-increases-letters-of-interest-for-the-graphite-one-supply-chain-to-2-07-billion-836518619.html

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025

Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed

LONDON and PHILADELPHIA - December 17, 2025 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study.

Faridoxorubicin is the first peptide drug conjugate (PDC) in Avacta's pipeline. It consists of doxorubicin conjugated with Avacta's proprietary pre|CISION® peptide and is specifically cleaved (released) by fibroblast activation protein-alpha (FAP), which is over-expressed in the tumor microenvironment, enabling targeted release of the doxorubicin payload.

SGC accounts for 6-8% of head and neck cancers, with approximately 2,500 cases diagnosed in the U.S. each year.1 SGC is a disease that does not respond to chemotherapy, has no standard therapy defined in the metastatic setting and a five-year survival rate of approximately 42%2 in advanced stage disease.

Avacta's recent data demonstrate continued robust and meaningful tumor shrinkage in patients with SGCs and a combined disease control rate of 90% across Phase 1a and Phase 1b patients.

Based on the preliminary favorable efficacy and safety data observed in the Phase 1b cohort in this part of the trial, enrollment will continue in this cohort with further data updates across the Phase 1a and Phase 1b cohorts expected in 1H 2026.

Christina Coughlin MD, PhD, CEO of Avacta, commented:

"These data continue to reinforce our belief in the transformative potential of our pre|CISION® peptide drug conjugates to expand the therapeutic index and increase the efficacy of highly potent therapeutics and further strengthens our confidence across our broader pipeline.

"SGC cancer is a devastating disease with no established standard of care treatment options. The clinically meaningful tumor shrinkage and prolonged progression free survival we have observed in the study highlight faridoxorubicin's potential as an important new treatment option for patients with SGC and other solid tumors. The Phase 1b data will mature as we continue to collect the survival data in this cohort.

"Translational data collected from this population continue to demonstrate the power of our pre|CISION® platform, with optimal payload release observed even at the lowest levels of FAP expression. T

US Investment incoming

I'm expecting mote news on other US listing before Christmas-2026 is going to be epic imho